Quick Answer
ENDONOVO THERAPEUTICS, INC. reported Revenue (ASC 606) of $135.4 thousand for fiscal year 2022.
ENDONOVO THERAPEUTICS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2022 | $135.4K | +85.2% |
| 2021 | $73.1K | -55.9% |
| 2020 | $165.8K | -46.5% |
| 2019 | $310.2K | +272.5% |
| 2018 | $83.3K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $1.5K | -86.1% | -96.6% |
| June 30, 2023 | $45.2K | +6853.8% | -48.4% |
| March 31, 2023 | $87.5K | +3736.1% | +698.7% |
| September 30, 2022 | $11.0K | +40.7% | +1586.2% |
| June 30, 2022 | $650.00 | -97.9% | -71.5% |
| March 31, 2022 | $2.3K | -93.4% | -70.7% |
| September 30, 2021 | $7.8K | -80.5% | -74.3% |
| June 30, 2021 | $30.3K | -32.1% | -12.8% |
- ENDONOVO THERAPEUTICS, INC. showed an increase of +85.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2022 period, ENDONOVO THERAPEUTICS, INC.’s revenue (asc 606) has grown by 62.6% (from $83.3 thousand to $135.4 thousand).
- The most recent figure is from ENDONOVO THERAPEUTICS, INC.’s fiscal year 2022 report (Form 10-K), filed with the SEC on April 17, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: